Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash from Operations (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Cash from Operations for 16 consecutive years, with 5600000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 103.05% to 5600000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1000000.0 through Dec 2025, up 127.46% year-over-year, with the annual reading at 1000000.0 for FY2025, 127.46% up from the prior year.
  • Cash from Operations for Q4 2025 was 5600000.0 at Gyre Therapeutics, down from 4641000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 42298000.0 in Q4 2022, with the low at 24356000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 2491350.0, with a median of 1429000.0 recorded in 2024.
  • The sharpest move saw Cash from Operations crashed 408.48% in 2021, then soared 339.3% in 2022.
  • Over 5 years, Cash from Operations stood at 17676000.0 in 2021, then skyrocketed by 339.3% to 42298000.0 in 2022, then plummeted by 92.06% to 3360000.0 in 2023, then tumbled by 182.08% to 2758000.0 in 2024, then tumbled by 103.05% to 5600000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 5600000.0, 4641000.0, and 2059000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.